DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Anturane (Sulfinpyrazone) - Summary

 
 



ANTURANE SUMMARY

Anturane®

Anturane, sulfinpyrazone USP, is a uricosuric agent available as 100-mg tablets and 200-mg capsules for oral administration.

Anturane is indicated for the treatment of:

  1. Chronic gouty arthritis
  2. Intermittent gouty arthritis

See all Anturane indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Anturane (Sulfinpyrazone)

Gout Attacks Twice as Likely at Night
Source: Medscape Rheumatology Headlines [2014.12.15]
Nocturnal acute gout attacks were 2.36 times more common than daytime attacks, and researchers recommended timing preventive drug therapy accordingly.
Medscape Medical News

Gout Attacks More Common at Night: Study
Source: MedicineNet Arthritis Specialty [2014.12.12]
Title: Gout Attacks More Common at Night: Study
Category: Health News
Created: 12/11/2014 12:00:00 AM
Last Editorial Review: 12/12/2014 12:00:00 AM

Nighttime gout attack risk more than two times higher than in the daytime
Source: Arthritis / Rheumatology News From Medical News Today [2014.12.11]
Novel research reveals that the risk of acute gout attacks is more than two times higher during the night or early morning hours than it is in the daytime.

Gout: data from Phase III studies of lesinurad in combination with allopurinol
Source: Gout News From Medical News Today [2014.11.19]
AstraZeneca has presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination...

Pseudogout
Source: MedicineNet Amyloidosis Specialty [2014.10.14]
Title: Pseudogout
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/14/2014 12:00:00 AM

more news >>

Published Studies Related to Anturane (Sulfinpyrazone)

The effect of sulfinpyrazone on treadmill exercise-induced angina pectoris. [1993]
Suspecting that platelet thromboemboli could play a role in the pathogenesis of myocardial ischemia, we have done a random-order, double-blind, crossover study of the effect of the platelet-active drug sulfinpyrazone on treadmill exercise-induced angina pectoris in 30 men with coronary artery disease.

Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. [2000.12]
BACKGROUND: Management of cyclosporine (CsA)-associated hyperuricemia in heart transplantation (HT) is difficult. Because of the myelotoxicity of combined allopurinol and azathioprine, we tested sulfinpyrazone... However, this drug reduced CsA levels, thus the risk of rejection is present.

Effects of sulfinpyrazone on retinal damage induced by experimental diabetes mellitus in rabbits. [1998.08]
The protective activity of the phenylbutazone derivative, sulfinpyrazone on retinal lesions has been assessed in rabbits with severe streptozotocin-induced diabetes. Sulfinpyrazone (8 mg kg-1 per day per os) was administered in diabetic animals in two different experimental procedures: for 135 days in a preventive approach (beginning on the day of initial hyperglicaemia); and for 30 days in a therapeutic approach (beginning on the day of appearance of severe retinal damage)...

Acute renal failure due to sulfinpyrazone. [1998.05]
A case of sulfinpyrazone-associated acute renal failure is reported. Sulfinpyrazone can cause reversible acute renal failure from acute tubular necrosis in patients with volume depletion.The patients at risk for acute renal failure due to sulfinpyrazone are those who have intravascular volume depletion as sensed by the kidneys.

Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. [1991.06.15]
We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis... A relatively high rate of complications, particularly mild gastrointestinal bleeding, was noted in patients on aspirin/sulfinpyrazone that could not be predicted on the basis of pre-treatment hemostatic test results.

more studies >>


Page last updated: 2014-12-15

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014